candesartan has been researched along with Nephrosis in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Nephrosis: Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with control group and nephrotic group received enalapril alone respectively, Tmax of enalaprilat in nephrotic group received both enalapril and candesartan cilexetil prolonged about 21." | 1.38 | The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats. ( Bi, BT; Lin, HB; Lin, T; Ma, AD; Xu, JP; Yang, XM; Yang, YB, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, BT | 1 |
| Yang, YB | 1 |
| Ma, AD | 1 |
| Lin, T | 1 |
| Lin, HB | 1 |
| Yang, XM | 1 |
| Xu, JP | 1 |
1 other study available for candesartan and Nephrosis
| Article | Year |
|---|---|
The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2012 |